The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
Official Title: GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma: A Multicentre Canadian Phase II Study
Study ID: NCT04472910
Brief Summary: To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions. The design of this prospective trial will also test our important hypotheses regarding the use of biomarkers to understand the benefit of mFFX in improving outcomes for patients with resectable pancreas cancer. Data from this study would likely inform future studies where patients are given personalised options for the best treatment strategies rather than one empiric approach.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
BC Cancer Agency Vancouver, Vancouver, British Columbia, Canada
Kingston Health Sciences Centre, Kingston, Ontario, Canada
London Health Sciences Centre, London, Ontario, Canada
Ottawa Hospital, Ottawa, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Sunnybrook Hospital/Odette Cancer Centre, Toronto, Ontario, Canada
Unity Health (St. Joseph's and St. Michael's), Toronto, Ontario, Canada
Jewish General Hospital, Montréal, Quebec, Canada
Name: Jennifer Knox, MD
Affiliation: Princess Margaret Cancer Centre, University Health Network
Role: PRINCIPAL_INVESTIGATOR